FG-4592: Phase II resumed

FDA lifted a clinical hold on FG-4592 and another oral HIF-PH inhibitor, FG-2216 (YM 311), that are in Phase II testing to treat anemia in CKD patients. Last May, FDA placed a clinical hold on both p...